Is SUVmax a useful marker for progression-free survival in patients with metastatic GEP-NET receiving (177)Lu-DOTATATE therapy?

Teker F, Elboga U

DOI: 10.1967/s002449912352
Published: 2021 May-Aug
Container: Hellenic journal of nuclear medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1967/s002449912352,
  title = {Is SUVmax a useful marker for progression-free survival in patients with metastatic GEP-NET receiving (177)Lu-DOTATATE therapy?},
  author = {Teker F and Elboga U},
  year = {2021},
  journal = {Hellenic journal of nuclear medicine},
  doi = {10.1967/s002449912352},
  url = {https://doi.org/10.1967/s002449912352}
}

RIS

TY  - JOUR
TI  - Is SUVmax a useful marker for progression-free survival in patients with metastatic GEP-NET receiving (177)Lu-DOTATATE therapy?
AU  - Teker F
AU  - Elboga U
PY  - 2021
JO  - Hellenic journal of nuclear medicine
DO  - 10.1967/s002449912352
UR  - https://doi.org/10.1967/s002449912352
ER  -

APA

F, T., & U, E. (2021). Is SUVmax a useful marker for progression-free survival in patients with metastatic GEP-NET receiving (177)Lu-DOTATATE therapy?. Hellenic journal of nuclear medicine. https://doi.org/10.1967/s002449912352

Source records

pubmed · retrieved 2026-09-27T00:31:59.381Z